A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Latest Information Update: 20 Feb 2024
Price :
$35 *
At a glance
- Drugs Ghrelin (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- Sponsors Asubio Pharmaceuticals; Daiichi Sankyo Company
- 22 Dec 2014 New trial record